Search Results - "VAUGHAN TUOHY, C"

Hypertrophic cardiomyopathy: the future of treatment by Tuohy, C. Vaughan, Kaul, Sanjiv, Song, Howard K., Nazer, Babak, Heitner, Stephen B.

“…Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused by sarcomeric mutations resulting in left ventricular hypertrophy,…”
Get full text

Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications by YANK, Veronica, VAUGHAN TUOHY, C, OWENS, Douglas K, STAFFORD, Randall S, LOGAN, Aaron C, BRAVATA, Dena M, STAUDENMAYER, Kristan, EISENHUT, Robin, SUNDARAM, Vandana, MCMAHON, Donal, OLKIN, Ingram, MCDONALD, Kathryn M

“…Recombinant factor VIIa (rFVIIa), a hemostatic agent approved for hemophilia, is increasingly used for off-label indications. To evaluate the benefits and…”
Get full text

Sleep disordered breathing and cardiovascular risk in older patients initiating dialysis in the United States: a retrospective observational study using medicare data by Tuohy, C Vaughan, Montez-Rath, Maria E, Turakhia, Mintu, Chang, Tara I, Winkelman, John W, Winkelmayer, Wolfgang C

“…Sleep disordered breathing (SDB) such as sleep apnea is associated with cardiovascular disease in the general population. However, little is known about the…”
Get full text

Use of Intraoperative Dobutamine Stress Echocardiography on Outcomes of Septal Myectomy by Bonanno, Alicia M., Macfie, Rebekah, Yadava, Mrinal, Fischer, Katherine, Mannello, Meghan, Tuohy, C. Vaughan, Dewey, Elizabeth, Masri, Ahmad, Heitner, Stephen B., Song, Howard K.

“…Septal myectomy is the standard treatment for obstructive hypertrophic cardiomyopathy. We studied the impact of intraoperative pre- and postprocedure…”
Get full text

Comparative Effectiveness Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications by Yank, Veronica, Tuohy, C. Vaughan, Logan, Aaron C., Bravata, Dena M., Staudenmayer, Kristan, Eisenhut, Robin, Sundaram, Vandana, McMahon, Donal, Olkin, Ingram, McDonald, Kathryn M., Owens, Douglas K., Stafford, Randall S.

Get full text

Comparison of Thromboembolic Event Rates in Randomized Controlled Trials and Observational Studies of Recombinant Factor VIIa for Off-Label Indications by Yank, Veronica, Logan, Aaron C., Tuohy, C. Vaughan, Bravata, Dena M., Staudenmayer, Kristan, Eisenhut, Robin, Sundaram, Vandana, McMahon, Donal, McDonald, Kathryn M., Owens, Douglas, Stafford, Randall S.

“…Abstract 1403 Poster Board I-425 Recombinant factor VIIa (rFVIIa) is a potent hemostatic agent licensed for treatment of bleeding in hemophiliac patients with…”
Get full text